Peptichemio in the therapy of malignancies (phase-I-study). The evaluation committee.
D001792:Blood Platelets / Q000648:ultrastructure; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002455:Cell Division / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D002875:Chromosomes / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008223:Lymphoma / Q000188:drug therapy; D008854:Microscopy, Electron; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010649:Phenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D007166:Immunosuppressive Agents; D009588:Nitrogen Mustard Compounds; D010455:Peptides; D014316:Tritium; D010649:Phenylalanine; D013936:Thymidine